All results
15 results
-
AEVI-007
The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease. ### Inclusion Criteria: 1.…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
ALXN2050-NEPH-201
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
ATYR
This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK),…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
DREAM
The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Efficacy and Safety of AMG 570 in Subjects With Active SLE
The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder
The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
First-In-Human Study of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
This study is an international, multi-center, study of Pompe disease patients that are currently receiving enzyme-replacement therapy (ERT). The purpose of…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
HEAL-IST
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Kinect-HD2
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
PVT-2201-301
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with…
- Ages
- 18 Years - 75 Years
- Sexes
- All